Compare ADMA Biologics Inc (ADMA) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Firy Inc. — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while Firy Inc. trades at $10 (market cap $159.51M). The key difference: ADMA Biologics Inc is far larger — about 13.9× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | FIRY | |
|---|---|---|
Market Cap | $2.22B | $159.51M |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $12.45 |
52-Week Low | $7.60 | $2.28 |
Enterprise Value | $2.29B | $103.18M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
FIRY trades at $9.98, down 4.77% in the last 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 revenue growth and a slight earnings beat, yet maintains negative net income margins and cash flow challenges. Recent news includes a legal victory awarding $719 million and a rebrand from Skillz Inc.
Outlook remains cautious due to persistent losses and cash burn, though the legal win provides a liquidity boost. Risks include high SG&A costs and competitive pressures, while analyst sentiment is mixed with a majority hold rating. Investors should weigh the potential from strategic shifts against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
